https://www.pharmaceutical-technology.com/data-insights/ixazomib-citrate-millennium-pharmaceuticals-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval-2/
Ixazomib citrate is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS).
ixazomib citratemillennium pharmaceuticalsrelapsing remittingmultiple sclerosis
https://www.pharmaceutical-technology.com/data-insights/ank-700-anokion-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/
ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS).
relapsing remittingmultiple sclerosisankrrms
https://www.sharecare.com/multiple-sclerosis/video-ways-reduce-relapse-rrms
Relapsing-remitting multiple sclerosis, or RRMS, is the most common form of MS and is characterized by attacks, or relapses, of new and worsening neurological...
waysreducerelapserrmssharecare
https://www.sharecare.com/multiple-sclerosis/video-what-should-care-partner-know-rrms
Being diagnosed with relapsing-remitting multiple sclerosis, or RRMS, can affect your entire family. In this video, Mitzi Joi Williams, MD, explains the...
care partnerknowrrmssharecare